Delix Therapeutics

Delix Therapeutics is a Boston-based drug discovery company pioneering a new class of compounds designed to deliver the therapeutic benefits of psychedelics without the accompanying hallucinogenic effects. The company's core technology centers on psychoplastogenic molecules that promote neural plasticity by targeting the TrkB receptor, a key mediator of brain-derived neurotrophic factor signaling. These compounds are engineered to stimulate the structural and functional rewiring of neural circuits associated with recovery from depression, addiction, and other neurological disorders. By decoupling the plasticity-promoting mechanisms of psychedelics from their perceptual side effects, Delix has created a drug development platform with broad therapeutic applicability.

Delix Therapeutics has established a strong foundation in the competitive neuropsychiatry landscape, having secured a $70 million Series A funding round to advance its pipeline toward clinical development. The company is backed by prominent investors who recognize the commercial and medical potential of non-hallucinogenic psychoplastogens as a next-generation alternative to both conventional antidepressants and full-dose psychedelic therapies. Their preclinical work has demonstrated that TrkB-targeting molecules can produce rapid and durable antidepressant-like effects in animal models, supporting the translation of their science into human studies. Delix is actively building out its medicinal chemistry capabilities and expanding its compound library as it moves toward IND-enabling studies.

Delix Therapeutics represents a significant inflection point for the neurotech and neuropsychiatry industries by addressing one of the most critical barriers to mainstream psychedelic medicine, namely the requirement for intensive clinical supervision during hallucinogenic experiences. Their approach could dramatically expand patient access, reduce the cost of treatment delivery, and open regulatory pathways that are far more straightforward than those faced by traditional psychedelic therapies. At a time when mental health disorders represent one of the largest unmet medical needs globally, a scalable, non-hallucinogenic plastogen could redefine the standard of care. Delix's platform positions it as a foundational company in the emerging field of neuroplasticity-based medicine.